U.S. group says Novartis MS drug price out of line with benefit
ZURICH (Reuters) – A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new multiple…
by October Gallery
by October Gallery
ZURICH (Reuters) – A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new multiple…